Close Menu
Aviation Analysis – Industry Travel NewsAviation Analysis – Industry Travel News
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Aviation Analysis – Industry Travel NewsAviation Analysis – Industry Travel News
    Subscribe
    • Home
    • Top News
    • World
    • Economy
    • Science
    • Tech
    • Sport
    • Entertainment
    • Contact Form
    Aviation Analysis – Industry Travel NewsAviation Analysis – Industry Travel News
    Home»Economy»The Oxford AstraZeneca University COVID-19 vaccine will begin manufacturing in Australia this week
    Economy

    The Oxford AstraZeneca University COVID-19 vaccine will begin manufacturing in Australia this week

    Jeffrey ClarkBy Jeffrey ClarkNovember 8, 2020No Comments1 Min Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Email
    The Oxford AstraZeneca University COVID-19 vaccine will begin manufacturing in Australia this week
    Share
    Facebook Twitter LinkedIn Pinterest Email Copy Link

    The COVID-19 vaccine has not yet received clinical approval, but doses will start manufacturing in Australia this week.

    CSL confirmed Sunday that it will start manufacturing the coronavirus vaccine at the University of Oxford / AstraZeneca in Victoria, starting Monday.

    The ASX-listed biotech company has separate contracts with AstraZeneca and the federal government to manufacture nearly 30 million doses of the AZD1222 vaccine.

    The first doses are scheduled to be launched in the first half of 2021, pending clinical trial outcome and regulatory approval.

    The vaccine will not be released for use until clinical trials and relevant manufacturing data are reviewed and approved by the Therapeutic Goods Administration.

    CSL will manufacture the AstraZeneca COVID-19 vaccine in Australia.
    CSL will start making the AstraZeneca COVID-19 Candidate vaccine in Australia from Monday. credit: Reuters

    Dr Andrew Nash, CSL’s chief science officer, said the announcement marked an important milestone and the end of “several months of round the clock preparation”.

    “There is still a long way to go and our first priority remains firmly the safety and efficacy of our vaccines,” Dr. Nash said in a statement on Sunday.

    “We are carrying out these manufacturing activities at risk and in parallel with clinical trial and approval processes in appreciation of the high urgency of the COVID-19 pandemic.”

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Jeffrey Clark

    Avid music fanatic. Communicator. Social media expert. Award-winning bacon scholar. Alcohol fan.

    Related Posts

    USDA Expands Food Safety Certification Assistance to Medium-Sized Specialty Crop Growers

    August 21, 2025

    USDA Reminds Farmers of Compliance Rules for Land and Wetland Conservation Programs

    August 21, 2025

    USDA’s Farm Storage Loan Program Marks 25 Years of Supporting Farmers

    August 21, 2025
    Navigate
    • Home
    • Top News
    • World
    • Economy
    • Science
    • Tech
    • Sport
    • Entertainment
    • Contact Form
    Pages
    • About Us
    • DMCA
    • Contact Form
    • Privacy Policy
    • Editorial Policy
    STAY UPTODATE

    Get the Latest News With Aviationanalysis.net

    OFFICE

    X. Herald Inc.
    114 5th Ave New York,
    NY 10011, United States

    QUERIES?

    Do you have any queries? Feel free to contact us via our Contact Form

    Visit Our Office

    X. Herald Inc.
    114 5th Ave New York,
    NY 10011, United States

    • About Us
    • DMCA
    • Contact Form
    • Privacy Policy
    • Editorial Policy
    © 2025 ThemeSphere. Designed by ThemeSphere.

    Type above and press Enter to search. Press Esc to cancel.